Sanford Health: FDA Approves Umbilical Stem Cell Research for COVID-19
May 15, 2020
May 15, 2020
SIOUX FALLS, South Dakota, May 15 -- Sanford Health issued the following news:
RESTEM, a leading cell-based therapeutics company, announced it has received approval from the U.S. Food and Drug Administration for a 60-patient Phase I/IIa study using umbilical cord mesenchymal stem cells to treat patients with severe cases of COVID-19. The study will be the first of its kind in the U.S.
The study is expected to start enrolling patients from Baptist Health South Florida an . . .
RESTEM, a leading cell-based therapeutics company, announced it has received approval from the U.S. Food and Drug Administration for a 60-patient Phase I/IIa study using umbilical cord mesenchymal stem cells to treat patients with severe cases of COVID-19. The study will be the first of its kind in the U.S.
The study is expected to start enrolling patients from Baptist Health South Florida an . . .